Rituximab for the treatment of myasthenia gravis a review of clinical effectiveness, cost-effectiveness, and guidelines
The purpose of this report is to review the clinical effectiveness and cost-effectiveness of rituximab therapy for the treatment of myasthenia gravis (MG). Additionally, this report aims to review the evidence-based guidelines regarding the use of rituximab for the treatment of MG. This report updat...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
August 14, 2018, 2018
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The purpose of this report is to review the clinical effectiveness and cost-effectiveness of rituximab therapy for the treatment of myasthenia gravis (MG). Additionally, this report aims to review the evidence-based guidelines regarding the use of rituximab for the treatment of MG. This report updates a previous CADTH report and in addition has a broader scope |
|---|---|
| Physical Description: | 1 PDF file (41 pages) illustrations |